Evidence map›Paper›PMID 32648951›Full record

ArticleAddiction (Abingdon, England)2021

Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study.

Lili Zhou, Sandipan Bhattacharjee, C Kent Kwoh, Patrick J Tighe, Gary M Reisfield, Daniel C Malone, Marion Slack, Debbie L Wilson, Ching-Yuan Chang, Wei-Hsuan Lo-Ciganic

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Gabapentinoid Prescribing Practices at a Large Academic Medical Center.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Lili ZhouDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.ORCID 0000-0002-9568-1325
Sandipan BhattacharjeeDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.ORCID 0000-0003-4917-5138
C Kent KwohDepartment of Medicine, Division of Rheumatology, College of Medicine, University of Arizona, Tucson, AZ, USA.ORCID 0000-0001-5937-550X
Patrick J TigheDepartment of Anesthesiology, College of Medicine, University of Florida, Gainesville, FL, USA.
Gary M ReisfieldDivisions of Addiction Medicine and Forensic Psychiatry, Departments of Psychiatry and Anesthesiology, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-5022-5430
Daniel C MaloneDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Marion SlackDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Debbie L WilsonDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-1640-5497
Ching-Yuan ChangDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-9585-6340
Wei-Hsuan Lo-CiganicDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-6590-4770

Funding

Using a predicting Risky Opioid-Benzodiazepine Trajectory e-Care Tool (PROTeCT) to identify high-risk regionsR21AG060308 · NIA · UNIVERSITY OF FLORIDA · PI LO-CIGANIC, WEI-HSUAN · 2019 to 2020
$523k
NIA NIH HHS R21 AG060308
6 · The paper itself

Abstract

BACKGROUND AND

aimsLittle is known about opioid and gabapentinoid (OPI-GABA) use duration and dose patterns' associations with adverse outcome risks. We examined associations between OPI-GABA dose and duration trajectories and subsequent drug overdose.

designRetrospective cohort study.

settingUS Medicare.

participantsUsing a 5% sample (2011-16), we identified 71 005 fee-for-service Medicare beneficiaries with fibromyalgia, low back pain, neuropathy and/or osteoarthritis initiating OPIs and/or GABAs [mean age ± standard deviation (SD) = 65.5 ± 14.5 years, female = 68.1%, white = 76.8%]. MEASUREMENTS: Group-based multi-trajectory models identified distinct OPI-GABA use patterns during the year of OPI and/or GABA initiation, based on weekly average standardized daily dose (i.e. OPIs = morphine milligram equivalent, GABAs = minimum effective daily dose). We estimated models with three to 12 trajectories and selected the best model based on Bayesian information criterion (BIC) and Nagin's criteria. We estimated risk of time to first drug overdose diagnosis within 12 months following the index year, adjusting for socio-demographic and health factors using inverse probability of treatment weighted multivariable Cox proportional hazards models.

findingsWe identified 10 distinct trajectories (BIC = -1 176 954; OPI-only = 3, GABA-only = 3, OPI-GABA = 4). Compared with OPI-only early discontinuers (40.6% of the cohort), 1-year drug overdose risk varied by trajectory group: consistent low-dose OPI-only users [16.6%; hazard ratio (HR) = 1.47, 95% confidence interval (CI) = 1.19-1.82], consistent high-dose OPI-only users (1.8%; HR = 4.57, 95% CI = 2.99-6.98), GABA-only early discontinuers (12.5%; HR = 1.39, 95% CI = 1.09-1.77), consistent low-dose GABA-only users (11.0%; HR = 1.44, 95% CI = 1.12-1.85), consistent high-dose GABA-only users (3.1%; HR = 1.43, 95% CI = 0.94-2.17), early discontinuation of OPIs and consistent low-dose GABA users (6.9%; HR = 1.24, 95% CI = 0.90-1.69), consistent low-dose OPI-GABA users (3.4%; HR = 2.49, 95% CI = 1.76-3.52), consistent low-dose OPI and high-dose GABA users (3.2%; HR = 2.46, 95% CI = 1.71-3.53) and consistent high-dose OPI and moderate-dose GABA users (0.9%; HR = 7.22, 95% CI = 4.46-11.69).

conclusionsRisk of drug overdose varied substantially among US Medicare beneficiaries on different use trajectories of opioids and gabapentinoids. High-dose opioid-only users and all consistent opioid and gabapentinoid users (regardless of doses) had more than double the risk of subsequent drug overdose compared with opioid-only early discontinuers.

Indexed as

Analgesics, OpioidDrug OverdoseAgedBayes TheoremCohort StudiesFemaleHumansInfant, NewbornMedicareRetrospective StudiesUnited StatesAnalgesics, OpioidgabapentinoidsMedicareopioidsoverdosesubstance use disorderstrajectories

Identifiers

PMID32648951
PMCPMC7796992

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.